Molecular Endocrinology, Vol 6, 1381-1392, Copyright © 1992 by Endocrine Society

ARTICLES

Alanine-scanning mutagenesis of human prolactin: importance of the 58- 74 region for bioactivity

V Goffin, M Norman and JA Martial
Laboratory of Molecular Biology and Genetic Engineering, University of Liege, Sart Tilman, Belgium.

We have generated 10 alanine mutants of human PRL (hPRL), a member of the PRL/GH family, to investigate the involvement of the highly conserved 58-74 region in the biological behavior of the protein. When treated with polyclonal anti-hPRL antibodies, all mutants were immunologically indistinguishable from the unmodified hPRL, and circular dichroism analyses indicated that their alpha-helix content was similar to that of the unmodified hormone. Mutations C58A, K69A, and, to a lesser extent, P66A affected drastically the ability of hPRL first to bind to the lactogenic receptor and second to stimulate the proliferation of Nb2 lymphoma cells, proving the importance of the 58- 74 peptide segment for hPRL bioactivity. Binding affinities of these mutants to the Nb2 lactogenic receptor have been compared to lactogenic binding data previously obtained for several mutants of hGH. The comparison reveals that the residues involved in the biological properties of the two proteins are not at topologically equivalent positions. Hence, we suggest that the binding of these hormones to the lactogenic receptors occurs through a different molecular mechanism having distinct requirements at the residue level.

This article has been cited by other articles:

				L. A. Svensson, K. Bondensgaard, L. Norskov-Lauritsen, L. Christensen, P. Becker, M. D. Andersen, M. J. Maltesen, K. D. Rand, and J. Breinholt Crystal Structure of a Prolactin Receptor Antagonist Bound to the Extracellular Domain of the Prolactin Receptor J. Biol. Chem., July 4, 2008; 283(27): 19085 - 19094. [Abstract] [Full Text] [PDF]

				F E Utama, M J LeBaron, L M Neilson, A S Sultan, A F Parlow, K-U Wagner, and H Rui Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J. Endocrinol., March 1, 2006; 188(3): 589 - 601. [Abstract] [Full Text] [PDF]

				J. F. Langenheim, D. Tan, A. M. Walker, and W. Y. Chen Two Wrongs Can Make a Right: Dimers of Prolactin and Growth Hormone Receptor Antagonists Behave as Agonists Mol. Endocrinol., March 1, 2006; 20(3): 661 - 674. [Abstract] [Full Text] [PDF]

				V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF]

				F.C. Peterson and C.L. Brooks Different elements of mini-helix 1 are required for human growth hormone or prolactin action via the prolactin receptor Protein Eng. Des. Sel., May 1, 2004; 17(5): 417 - 424. [Abstract] [Full Text] [PDF]

				S. Bernichtein, C. Kayser, K. Dillner, S. Moulin, J. J. Kopchick, J. A. Martial, G. Norstedt, O. Isaksson, P. A. Kelly, and V. Goffin Development of Pure Prolactin Receptor Antagonists J. Biol. Chem., September 19, 2003; 278(38): 35988 - 35999. [Abstract] [Full Text] [PDF]

				S. Bernichtein, S. Kinet, S. Jeay, M. Llovera, D. Madern, J. A. Martial, P. A. Kelly, and V. Goffin S179D-Human PRL, a Pseudophosphorylated Human PRL Analog, Is an Agonist and Not an Antagonist Endocrinology, September 1, 2001; 142(9): 3950 - 3963. [Abstract] [Full Text] [PDF]

				W. Y. Chen, P. Ramamoorthy, N.-y. Chen, R. Sticca, and T. E. Wagner A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis Clin. Cancer Res., November 1, 1999; 5(11): 3583 - 3593. [Abstract] [Full Text] [PDF]

				S. Kinet, S. Bernichtein, P. A. Kelly, J. A. Martial, and V. Goffin Biological Properties of Human Prolactin Analogs Depend Not Only on Global Hormone Affinity, but Also on the Relative Affinities of Both Receptor Binding Sites J. Biol. Chem., September 10, 1999; 274(37): 26033 - 26043. [Abstract] [Full Text] [PDF]

				C. Bole-Feysot, V. Goffin, M. Edery, N. Binart, and P. A. Kelly Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice Endocr. Rev., June 1, 1998; 19(3): 225 - 268. [Abstract] [Full Text]

				T.-J. Chen, C. B. Kuo, K. F. Tsai, J.-W. Liu, D.-Y. Chen, and A. M. Walker Development of Recombinant Human Prolactin Receptor Antagonists by Molecular Mimicry of the Phosphorylated Hormone Endocrinology, February 1, 1998; 139(2): 609 - 616. [Abstract] [Full Text] [PDF]

				V. Goffin, S. Kinet, F. Ferrag, N. Binart, J. A. Martial, and P. A. Kelly Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay J. Biol. Chem., July 12, 1996; 271(28): 16573 - 16579. [Abstract] [Full Text] [PDF]

				S. Kinet, V. Goffin, V. Mainfroid, and J. A. Martial Characterization of Lactogen Receptor-binding Site 1of Human Prolactin J. Biol. Chem., June 14, 1996; 271(24): 14353 - 14360. [Abstract] [Full Text] [PDF]

				P. M. Maciejewski, F. C. Peterson, P. J. Anderson, and C. L. Brooks Mutation of Serine 90 to Glutamic Acid Mimics Phosphorylation of Bovine Prolactin J. Biol. Chem., November 17, 1995; 270(46): 27661 - 27665. [Abstract] [Full Text] [PDF]

				P. O. Olins, S. C. Bauer, S. Braford-Goldberg, K. Sterbenz, J. O. Polazzi, M. H. Caparon, B. K. Klein, A. M. Easton, K. Paik, J. A. Klover, et al. Saturation Mutagenesis of Human Interleukin-3 J. Biol. Chem., October 6, 1995; 270(40): 23754 - 23760. [Abstract] [Full Text] [PDF]